Sign In
Buy VCYT
$46.32
-13.46 (-22.52%)
At Close: Jul 31, 2026
Veracyte to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference
08:30am, Friday, 29'th Aug 2025
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) announced today that management will participate in a fireside chat at the Morgan Stanley 23rd Annual Global Healthcare Conf
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT--Veracyte Announces New Study in Cell Shows that Decipher Prostate Test Predicts Chemotherapy Benefit in Patients with Metastatic Prostate Cancer
Veracyte: Q2 Earnings Brings My Position Out Of Mothballs
10:18am, Tuesday, 26'th Aug 2025
Veracyte's Q2 results show strong revenue growth, margin expansion, and a robust cash position, reinforcing my long-term bullish outlook. Key growth drivers include Decipher's expansion, upcoming prod
Veracyte Completes NIGHTINGALE Clinical Utility Trial Enrollment for Percepta Nasal Swab Lung Cancer Test
08:30am, Tuesday, 26'th Aug 2025
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT--Veracyte Completes NIGHTINGALE Clinical Utility Trial Enrollment for Percepta Nasal Swab Lung Cancer Test.
Is the Options Market Predicting a Spike in Veracyte Stock?
10:11am, Monday, 25'th Aug 2025
Investors need to pay close attention to VCYT stock based on the movements in the options market lately.
Here's Why Veracyte (VCYT) is a Strong Momentum Stock
10:50am, Friday, 22'nd Aug 2025
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here's Why Veracyte (VCYT) is a Strong Growth Stock
10:46am, Friday, 15'th Aug 2025
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
VCYT Stock Gains on Q2 Earnings and Revenue Beat, Margins Up
09:26am, Tuesday, 12'th Aug 2025
Veracyte Q2 earnings and revenues beat estimates, fueled by Decipher and Afirma growth, sending shares up over 15%.
Veracyte, Inc. (VCYT) Q2 2025 Earnings Call Transcript
02:20am, Thursday, 07'th Aug 2025
Veracyte, Inc. (NASDAQ:VCYT ) Q2 2025 Earnings Conference Call August 6, 2025 4:30 PM ET Company Participants Marc A. Stapley - CEO & Director Phillip G.
Veracyte (VCYT) Q2 Revenue Jumps 14%
12:40am, Thursday, 07'th Aug 2025
Veracyte (VCYT) Q2 Revenue Jumps 14%
Veracyte (VCYT) Tops Q2 Earnings and Revenue Estimates
07:36pm, Wednesday, 06'th Aug 2025
Veracyte (VCYT) came out with quarterly earnings of $0.44 per share, beating the Zacks Consensus Estimate of $0.31 per share. This compares to earnings of $0.3 per share a year ago.
Veracyte Announces Second Quarter 2025 Financial Results
04:05pm, Wednesday, 06'th Aug 2025
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced financial results for the second quarter ended June 30, 2025. “Test
Veracyte (VCYT) Soars 7.0%: Is Further Upside Left in the Stock?
09:06am, Monday, 28'th Jul 2025
Veracyte (VCYT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Veracyte Set to Join S&P SmallCap 600
05:58pm, Thursday, 24'th Jul 2025
NEW YORK , July 24, 2025 /PRNewswire/ -- Veracyte Inc. (NASD: VCYT) will replace Triumph Group Inc. (NYSE: TGI) in the S&P SmallCap 600 effective prior to the opening of trading on Tuesday, July 29. W
Veracyte to Release Second Quarter 2025 Financial Results on August 6, 2025
05:30pm, Thursday, 17'th Jul 2025
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that it will release financial results for the second quarter of 2025
